Less than a year after completing its $256 million IPO, South San Francisco-based Tricida Inc. presented robust phase III extension data for its chronic kidney disease (CKD) and metabolic acidosis candidate, TRC-101 (veverimer), paving the way for a new drug application filing through an accelerated pathway in the second half of this year.